Since the credit crunch over a decade ago and one patent cliff after another*, US drug maker behemoth Pfizer has gone through its pipeline troubles seriously challenged, yet has emerged mostly unscathed.

And now, with the Covid-19 vaccine goldmine in sight**, the future may have a completely different taste if a) its magic dose receives the final, green light from the regulators and, equally important b) it gets the logistics angle of its business proposition right.

(*A bit of background is here: 2012, 2014, 2016, ...

Subscription required for Premium stories

In order to view the entire article please login with a valid subscription below or register an account and subscribe to Premium

Or buy full access to this story only for £13.00

Please login to activate the purchase link or sign up here to register an account

Premium subscriber
New Premium subscriber REGISTER

Comment on this article

You must be logged in to post a comment.